Opus Genetics Inc (IRD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.67+1.52%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IRD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -32.0% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 21.1% |
Growth built into the price is above our model estimate.
The price assumes 53.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
IRD — earnings in line
Dated 2026-08-06
of this Current Report on Form 8-K, and Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
Why it matters: This financing helps pay for operations and clinical programs. It will last until 2029.
Watch forCompany announces it closed the $35 million first part of financing.
Also watch forCompany does not get the expected financing or has delays.
Why it matters: A rebound in sector revenue growth may improve Opus Genetics' prospects. This could lead to better performance.
Supportive ifSector revenue growth speeds up to 10% or more.
Worry ifSector revenue growth keeps slowing down below 5%.
Why it matters: Securing funding is crucial for the company's operations and growth plans. It will show if they can sustain their business.
Supportive ifA press release or announcement confirming new funding of at least $10M.
Worry ifNo funding announcements made by the end of Q3 2026.
Why it matters: Advancing these programs could show that Opus Genetics is growing. It may lead to more money.
Supportive ifRDH12, MERTK, and RHO programs enter clinical testing as planned in late 2026.
Worry ifAny of these programs are delayed or fail to enter clinical testing.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$197 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $706 loss on $10,000 · 7.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,922 loss on $10,000 · 49.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Starting this trial is key for advancing the pipeline and could lead to significant future value.
Supportive ifClinical testing for OPGx-RDH12 begins as scheduled in Q4 2026.
Worry ifClinical testing is delayed or fails to start as planned.
Why it matters: This data will show how well the gene therapy works for patients. Positive results could boost confidence in the pipeline.
Supportive ifCohort 1 data shows a big improvement in vision after treatment.
Worry ifData shows no improvement or worse results in vision.
Why it matters: Starting dosing is a key step in the clinical trial process. It indicates progress toward potential approval.
Supportive ifDosing of OPGx-LCA5 begins as planned in Q4 2026.
Worry ifDosing is delayed or does not begin as planned.
Why it matters: Initiating clinical testing is crucial for advancing the RDH12 program. It shows the company is making progress.
Supportive ifClinical testing for RDH12 starts as planned in Q4 2026.
Worry ifClinical testing for RDH12 is postponed or canceled.